Details of the Drug

General Information of Drug (ID: DMCHV4I)

Drug Name
Rifapentine
Synonyms
RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE
Indication
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B1Z Approved [1]
Macular degeneration 9B78.3 Investigative [2]
Therapeutic Class
Antituberculosis Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 877
Topological Polar Surface Area (xlogp) 6.7
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 15
ADMET Property
Bioavailability
70% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The apparent oral clearance of drug is 2.51 +/- 0.14 L/h [4]
Metabolism
The drug is metabolized via the hepatic [5]
Vd
The volume of distribution (Vd) of drug is 70.2 +/- 9.1 L [4]
Chemical Identifiers
Formula
C47H64N4O12
IUPAC Name
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
Canonical SMILES
C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C
InChI
InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1
InChIKey
WDZCUPBHRAEYDL-GZAUEHORSA-N
Cross-matching ID
PubChem CID
135403821
ChEBI ID
CHEBI:45304
CAS Number
61379-65-5
DrugBank ID
DB01201
TTD ID
D0G9IU
INTEDE ID
DR1421
ACDINA ID
D00592

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Binder [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rifapentine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pretomanid DMDYA31 Major Increased metabolism of Rifapentine caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [19]
Coadministration of a Drug Treating the Disease Different from Rifapentine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased metabolism of Rifapentine caused by Remdesivir mediated induction of CYP450 enzyme. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [20]
Ivosidenib DM8S6T7 Major Increased metabolism of Rifapentine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [21]
Midostaurin DMI6E0R Major Increased metabolism of Rifapentine caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Gilteritinib DMWQ4MZ Major Increased metabolism of Rifapentine caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [23]
Oliceridine DM6MDCF Major Increased metabolism of Rifapentine caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [24]
Ivabradine DM0L594 Major Increased metabolism of Rifapentine caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [20]
Bepridil DM0RKS4 Major Increased metabolism of Rifapentine caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [25]
Dronedarone DMA8FS5 Moderate Increased metabolism of Rifapentine caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [26]
Posaconazole DMUL5EW Moderate Accelerated clearance of Rifapentine due to the transporter induction by Posaconazole. Aspergillosis [1F20] [20]
Clarithromycin DM4M1SG Moderate Increased metabolism of Rifapentine caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [27]
Troleandomycin DMUZNIG Moderate Increased metabolism of Rifapentine caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [27]
Cariprazine DMJYDVK Moderate Increased metabolism of Rifapentine caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [28]
Erdafitinib DMI782S Major Increased metabolism of Rifapentine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [29]
Pexidartinib DMS2J0Z Major Decreased metabolism of Rifapentine caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [30]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Rifapentine caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Lapatinib DM3BH1Y Moderate Increased metabolism of Rifapentine caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
LY2835219 DM93VBZ Major Increased metabolism of Rifapentine caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Rifapentine caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Tucatinib DMBESUA Major Increased metabolism of Rifapentine caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Palbociclib DMD7L94 Major Increased metabolism of Rifapentine caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Alpelisib DMEXMYK Major Increased metabolism of Rifapentine caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Rifapentine caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Rifapentine caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Bosutinib DMTI8YE Major Increased metabolism of Rifapentine caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Macitentan DMP79A1 Major Increased metabolism of Rifapentine caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [39]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Rifapentine caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [40]
PF-04449913 DMSB068 Major Increased metabolism of Rifapentine caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [41]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Rifapentine caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [42]
Regorafenib DMHSY1I Moderate Increased metabolism of Rifapentine caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [43]
Drospirenone DM1A9W3 Major Increased metabolism of Rifapentine caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [44]
Levonorgestrel DM1DP7T Major Increased metabolism of Rifapentine caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [44]
Ulipristal DMBNI20 Moderate Increased metabolism of Rifapentine caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [20]
Osilodrostat DMIJC9X Major Increased metabolism of Rifapentine caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [20]
Ivacaftor DMZC1HS Major Increased metabolism of Rifapentine caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Rifapentine caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [24]
Vilazodone DM4LECQ Moderate Increased metabolism of Rifapentine caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [45]
Vortioxetine DM6F1PU Moderate Increased metabolism of Rifapentine caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [46]
OPC-34712 DMHG57U Moderate Increased metabolism of Rifapentine caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [47]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Rifapentine caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [32]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Rifapentine caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [48]
Ospemifene DMC4GEI Moderate Increased metabolism of Rifapentine caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [49]
Ingrezza DMVPLNC Major Increased metabolism of Rifapentine caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [50]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Rifapentine caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [51]
Stiripentol DMMSDOY Major Increased metabolism of Rifapentine caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Rifapentine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Cannabidiol DM0659E Moderate Increased metabolism of Rifapentine caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [20]
Bay 80-6946 DMLOS5R Major Increased metabolism of Rifapentine caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [52]
Tazemetostat DMWP1BH Major Increased metabolism of Rifapentine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [53]
Solifenacin DMG592Q Moderate Increased metabolism of Rifapentine caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [54]
Mirabegron DMS1GYT Minor Increased metabolism of Rifapentine caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Ripretinib DM958QB Major Increased metabolism of Rifapentine caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [56]
Sunitinib DMCBJSR Major Increased metabolism of Rifapentine caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [32]
Avapritinib DMK2GZX Major Increased metabolism of Rifapentine caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [20]
Colchicine DM2POTE Moderate Increased metabolism of Rifapentine caused by Colchicine mediated induction of CYP450 enzyme. Gout [FA25] [27]
Boceprevir DMBSHMF Moderate Increased metabolism of Rifapentine caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
PSI-7977 DMLSUWZ Major Accelerated clearance of Rifapentine due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [32]
Simeprevir DMLUA9D Major Increased metabolism of Rifapentine caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [58]
Telaprevir DMMRV29 Moderate Increased metabolism of Rifapentine caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
Daclatasvir DMSFK9V Major Increased metabolism of Rifapentine caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [20]
MK-1439 DM215WE Major Increased metabolism of Rifapentine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Fosamprenavir DM4W9B3 Major Increased metabolism of Rifapentine caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Fostemsavir DM50ILT Major Increased metabolism of Rifapentine caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Cobicistat DM6L4H2 Major Increased metabolism of Rifapentine caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Dolutegravir DMCZGRE Minor Increased metabolism of Rifapentine caused by Dolutegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [62]
Saquinavir DMG814N Major Increased metabolism of Rifapentine caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Elvitegravir DMG9B1U Major Increased metabolism of Rifapentine caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [32]
Etravirine DMGV8QU Major Increased metabolism of Rifapentine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Rilpivirine DMJ0QOW Major Increased metabolism of Rifapentine caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Darunavir DMN3GCH Major Increased metabolism of Rifapentine caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
GSK1265744 DMT8J0I Major Increased metabolism of Rifapentine caused by GSK1265744 mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [65]
Maraviroc DMTL94F Moderate Accelerated clearance of Rifapentine due to the transporter induction by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [32]
Raltegravir DMYURI6 Minor Increased metabolism of Rifapentine caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [24]
Levamlodipine DM92S6N Major Increased metabolism of Rifapentine caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [25]
Tolvaptan DMIWFRL Major Increased metabolism of Rifapentine caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [20]
Lesinurad DMUR64T Moderate Increased metabolism of Rifapentine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [66]
TP-434 DM5A31S Major Increased metabolism of Rifapentine caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [67]
Suvorexant DM0E6S3 Moderate Increased metabolism of Rifapentine caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [68]
Tasimelteon DMLOQ1V Major Increased metabolism of Rifapentine caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
ITI-007 DMUQ1DO Major Increased metabolism of Rifapentine caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [70]
Quazepam DMY4D87 Moderate Increased metabolism of Rifapentine caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [27]
Estazolam DMZGXUM Moderate Increased metabolism of Rifapentine caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [27]
Naloxegol DML0B41 Major Increased metabolism of Rifapentine caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [20]
Pemigatinib DM819JF Major Increased metabolism of Rifapentine caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [20]
Crizotinib DM4F29C Major Increased metabolism of Rifapentine caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [32]
Brigatinib DM7W94S Major Increased metabolism of Rifapentine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [71]
Ceritinib DMB920Z Moderate Increased metabolism of Rifapentine caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [72]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Rifapentine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [73]
PF-06463922 DMKM7EW Major Increased metabolism of Rifapentine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [74]
Osimertinib DMRJLAT Major Increased metabolism of Rifapentine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [32]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Rifapentine due to the transporter induction by BIBW 2992. Lung cancer [2C25] [75]
Pralsetinib DMWU0I2 Major Increased metabolism of Rifapentine caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Capmatinib DMYCXKL Major Increased metabolism of Rifapentine caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [77]
Selpercatinib DMZR15V Major Increased metabolism of Rifapentine caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [20]
Lumefantrine DM29GAD Moderate Increased metabolism of Rifapentine caused by Lumefantrine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [27]
Halofantrine DMOMK1V Moderate Increased metabolism of Rifapentine caused by Halofantrine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [27]
Hydroxychloroquine DMSIVND Moderate Increased metabolism of Rifapentine caused by Hydroxychloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [32]
Idelalisib DM602WT Moderate Increased metabolism of Rifapentine caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [78]
GDC-0199 DMH0QKA Major Increased metabolism of Rifapentine caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [79]
IPI-145 DMWA24P Major Increased metabolism of Rifapentine caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [80]
Acalabrutinib DM7GCVW Major Increased metabolism of Rifapentine caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [81]
Ibrutinib DMHZCPO Major Increased metabolism of Rifapentine caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [20]
Arry-162 DM1P6FR Moderate Increased metabolism of Rifapentine caused by Arry-162 mediated induction of UGT. Melanoma [2C30] [32]
Vemurafenib DM62UG5 Major Increased metabolism of Rifapentine caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [32]
Selumetinib DMC7W6R Major Increased metabolism of Rifapentine caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [82]
LGX818 DMNQXV8 Major Increased metabolism of Rifapentine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [83]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Rifapentine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [32]
Ubrogepant DM749I3 Major Increased metabolism of Rifapentine caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [84]
Rimegepant DMHOAUG Major Increased metabolism of Rifapentine caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [85]
Flibanserin DM70DTN Major Increased metabolism of Rifapentine caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [86]
Panobinostat DM58WKG Major Increased metabolism of Rifapentine caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [87]
Siponimod DM2R86O Major Increased metabolism of Rifapentine caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [32]
Romidepsin DMT5GNL Moderate Increased metabolism of Rifapentine caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [88]
Fedratinib DM4ZBK6 Major Increased metabolism of Rifapentine caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [20]
Nilotinib DM7HXWT Major Increased metabolism of Rifapentine caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [89]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Rifapentine caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [90]
Dasatinib DMJV2EK Major Increased metabolism of Rifapentine caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Rolapitant DM8XP26 Major Increased metabolism of Rifapentine caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [20]
Netupitant DMEKAYI Major Increased metabolism of Rifapentine caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [32]
Entrectinib DMMPTLH Major Increased metabolism of Rifapentine caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [91]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Rifapentine caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [92]
S-297995 DM26IH8 Major Increased metabolism of Rifapentine caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [93]
Olaparib DM8QB1D Major Increased metabolism of Rifapentine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [32]
Rucaparib DM9PVX8 Moderate Increased metabolism of Rifapentine caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [94]
Istradefylline DM20VSK Major Increased metabolism of Rifapentine caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [95]
Pimavanserin DMR7IVC Moderate Increased metabolism of Rifapentine caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [96]
Macimorelin DMQYJIR Moderate Increased metabolism of Rifapentine caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [97]
Lefamulin DME6G97 Major Increased metabolism of Rifapentine caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [98]
Ergonovine DM0VEC1 Moderate Increased metabolism of Rifapentine caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [32]
Lonafarnib DMGM2Z6 Major Increased metabolism of Rifapentine caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [99]
ABIRATERONE DM8V75C Major Increased metabolism of Rifapentine caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [100]
Enzalutamide DMGL19D Moderate Increased metabolism of Rifapentine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [101]
Relugolix DMK7IWL Major Increased metabolism of Rifapentine caused by Relugolix mediated induction of CYP450 enzyme. Prostate cancer [2C82] [102]
Darolutamide DMV7YFT Major Accelerated clearance of Rifapentine due to the transporter induction by Darolutamide. Prostate cancer [2C82] [103]
Silodosin DMJSBT6 Moderate Accelerated clearance of Rifapentine due to the transporter induction by Silodosin. Prostate hyperplasia [GA90] [32]
Apremilast DMTWS9E Moderate Increased metabolism of Rifapentine caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [104]
Selexipag DMAHSU0 Moderate Increased metabolism of Rifapentine caused by Selexipag mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [32]
Riociguat DMXBLMP Moderate Increased metabolism of Rifapentine caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [105]
Everolimus DM8X2EH Major Increased metabolism of Rifapentine caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [24]
Axitinib DMGVH6N Major Increased metabolism of Rifapentine caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [106]
Temsirolimus DMS104F Major Increased metabolism of Rifapentine caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [32]
Upadacitinib DM32B5U Major Increased metabolism of Rifapentine caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [107]
Tofacitinib DMBS370 Major Increased metabolism of Rifapentine caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [32]
Dexamethasone DMMWZET Moderate Increased metabolism of Rifapentine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [27]
Quetiapine DM1N62C Moderate Increased metabolism of Rifapentine caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [32]
Aripiprazole DM3NUMH Moderate Increased metabolism of Rifapentine caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [108]
Avanafil DM75CXN Moderate Increased metabolism of Rifapentine caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [109]
Voxelotor DMCS6M5 Major Increased metabolism of Rifapentine caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [110]
LDE225 DMM9F25 Major Increased metabolism of Rifapentine caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [111]
Larotrectinib DM26CQR Major Accelerated clearance of Rifapentine due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [32]
Docetaxel DMDI269 Moderate Increased metabolism of Rifapentine caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [112]
Trabectedin DMG3Y89 Moderate Increased metabolism of Rifapentine caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [20]
Armodafinil DMGB035 Moderate Increased metabolism of Rifapentine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [113]
LEE011 DMMX75K Major Increased metabolism of Rifapentine caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [114]
Vandetanib DMRICNP Moderate Increased metabolism of Rifapentine caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [115]
Taxol DMUOT9V Moderate Increased metabolism of Rifapentine caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [116]
Pitolisant DM8RFNJ Major Increased metabolism of Rifapentine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [20]
Pomalidomide DMTGBAX Moderate Increased metabolism of Rifapentine caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [117]
Fostamatinib DM6AUHV Major Increased metabolism of Rifapentine caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [118]
As-1670542 DMV05SW Major Increased metabolism of Rifapentine caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [119]
Apixaban DM89JLN Major Increased metabolism of Rifapentine caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [20]
Brilinta DMBR01X Major Increased metabolism of Rifapentine caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [120]
Cabozantinib DMIYDT4 Major Increased metabolism of Rifapentine caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [121]
Saxagliptin DMGXENV Moderate Increased metabolism of Rifapentine caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [122]
Linagliptin DMWFJTR Moderate Increased metabolism of Rifapentine caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [123]
Elagolix DMB2C0E Moderate Accelerated clearance of Rifapentine due to the transporter induction by Elagolix. Uterine fibroid [2E86] [124]
Betrixaban DM2C4RF Moderate Accelerated clearance of Rifapentine due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [125]
⏷ Show the Full List of 166 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Calcium stearate E00244 15324 lubricant
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium ascorbate E00554 23667548 Antioxidant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rifapentine 150 mg tablet 150 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.
7 Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9.
8 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
9 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
10 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
11 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
12 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
13 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
22 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
23 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
24 Canadian Pharmacists Association.
25 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
26 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
27 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
28 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
29 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
30 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
31 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
32 Cerner Multum, Inc. "Australian Product Information.".
33 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
34 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
35 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
36 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
38 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
40 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
41 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
43 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
44 Archer JS, Archer DF "Oral contraceptive efficacy and antibiotic interaction: A myth debunked." J Am Acad Dermatol 46 (2002): 917-23. [PMID: 12063491]
45 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
46 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
47 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
48 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
49 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
50 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
51 Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
52 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
53 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
54 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
55 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
56 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
57 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
58 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
59 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
60 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
61 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
62 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
63 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
64 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
65 Cerner Multum, Inc. "Canadian Product Information.".
66 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
67 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
68 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
69 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
70 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
71 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
72 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
73 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
74 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
76 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
77 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
78 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
79 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
80 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
81 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
82 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
83 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
84 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
85 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
86 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
87 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
88 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
89 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
90 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
91 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
92 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
93 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
94 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
95 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
96 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
97 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
98 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
99 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
100 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
101 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
102 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
103 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
104 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
105 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
106 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
107 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
108 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
109 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
110 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
111 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
112 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
113 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
114 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
115 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
116 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
117 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
118 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
119 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
120 Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
121 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
122 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
123 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
124 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
125 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]